TISSUE REGENIX HOLDINGS LIMITED
Get an alert when TISSUE REGENIX HOLDINGS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-04-23 (in 11mo)
Last made up 2026-04-09
Watchouts
Cash
—
Latest balance sheet
Net assets
£19M
+34.2% vs 2023
Employees
—
Average over period
Profit before tax
£5M
-45% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
3 officer resignations in last 12 months
Multiple officers have left the board recently — see the People section for who.
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | £7,465,530 | £3,394,366 | |
| Profit before tax | £8,933,284 | £4,914,010 | |
| Net profit | £8,933,284 | £4,914,010 | |
| Cash | — | — | |
| Total assets less current liabilities | — | — | |
| Net assets | £14,378,058 | £19,292,068 | |
| Equity | £14,378,058 | £19,292,068 | |
| Average employees | — | — | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Gearing (liabilities / total assets) | 66.2% | 57.4% |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- RSM UK Audit LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Company is a wholly owned subsidiary of Tissue Regenix Group plc and treasury matters are managed and controlled on a Group-wide basis. The Directors have considered their obligations in relation to their assessment of the going concern of the Group, and each statutory entity within it, and have reviewed the current budget cash forecasts and assumptions as well as the main risk factors facing the Group. Tissue Regenix Group plc has confirmed that it will continue to provide financial support to the Company for a period of at least twelve months from the date of approval of these financial statements. It will not demand repayment of any amount due to it such as to preclude the Company from continuing as a going concern. As at 31 December 2024, the Tissue Regenix Group had available cash and cash equivalents of USD1.9 million. The Directors are satisfied that Tissue Regenix Group plc is capable of providing the necessary financial support and that the Company, therefore, has adequate resources to continue in operational existence for the foreseeable future.”
Group structure
- TISSUE REGENIX HOLDINGS LIMITED · parent
- Tissue Regenix Holdings Inc 100%
- CellRight Technologies LLC 100%
Significant events
- “The Directors are not aware of any events that occurred after the reporting date that require reporting.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 11 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| LUND, Kirsten Mary | Secretary | 2019-12-20 | — | — |
| LECOQUE, Jay Charles | Director | 2025-09-04 | Nov 1962 | American |
| LUND, Kirsten Mary | Director | 2025-10-16 | Nov 1983 | British |
Show 11 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| DEVLIN, Paul John | Secretary | 2017-04-10 | 2018-01-31 |
| JONES, Gareth Hywel | Secretary | 2018-10-29 | 2019-12-20 |
| BARKER, Michael Denis | Director | 2019-08-28 | 2019-11-30 |
| COCKE, David Claiborne | Director | 2021-01-21 | 2025-07-31 |
| COULDWELL, Steven Ashley | Director | 2017-11-15 | 2019-07-31 |
| DEVLIN, Paul John | Director | 2017-04-10 | 2018-01-31 |
| GLENN, Jonathan Martin | Director | 2020-04-01 | 2025-09-05 |
| JONES, Gareth Hywel | Director | 2018-10-29 | 2020-11-24 |
| LEE, Daniel Ray | Director | 2020-11-16 | 2025-10-15 |
| ODELL, Antony Ruben | Director | 2017-04-10 | 2017-10-31 |
| SAMUEL, John Andrew Walter | Director | 2017-04-10 | 2020-03-20 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Tissue Regenix Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2017-04-10 | Active |
Filing timeline
Last 20 of 48 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-01-05 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2025-11-03 | AP01 | officers | Appoint person director company with name date | |
| 2025-11-03 | TM01 | officers | Termination director company with name termination date | |
| 2025-09-11 | AP01 | officers | Appoint person director company with name date | |
| 2025-09-11 | TM01 | officers | Termination director company with name termination date | |
| 2025-08-20 | AA | accounts | Accounts with accounts type full | |
| 2025-08-04 | TM01 | officers | Termination director company with name termination date | |
| 2025-04-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-04-18 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-04-03 | AA | accounts | Accounts with accounts type full | |
| 2023-04-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-03-28 | AA | accounts | Accounts with accounts type full | |
| 2023-01-31 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2023-01-31 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2022-09-20 | AA | accounts | Accounts with accounts type full | |
| 2022-04-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-09-25 | AA | accounts | Accounts with accounts type full | |
| 2021-05-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-02-03 | AP01 | officers | Appoint person director company with name date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 8
- Capital events
- 0
- Officers appointed
- 2
- Officers resigned
- 3
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
—
Not reported
-
Net assets
+34.2%
£14,378,058 £19,292,068
-
Employees
—
Not reported
-
Operating profit
-54.5%
£7,465,530 £3,394,366
-
Profit before tax
-45%
£8,933,284 £4,914,010
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers